What is Zacks Research’s Forecast for CRDF FY2027 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Investment analysts at Zacks Research cut their FY2027 earnings per share (EPS) estimates for Cardiff Oncology in a research note issued on Monday, March 2nd. Zacks Research analyst J. Vandermosten now expects that the company will earn ($0.75) per share for the year, down from their previous forecast of ($0.74). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share.

CRDF has been the subject of several other reports. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Wall Street Zen upgraded Cardiff Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday. Piper Sandler decreased their target price on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a report on Wednesday, January 21st. Finally, Noble Financial initiated coverage on Cardiff Oncology in a research report on Monday, January 5th. They issued an “outperform” rating and a $12.00 price target for the company. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Price Performance

Shares of CRDF opened at $1.98 on Wednesday. The firm’s 50 day moving average is $2.26 and its 200-day moving average is $2.24. The stock has a market capitalization of $135.35 million, a P/E ratio of -2.87 and a beta of 1.32. Cardiff Oncology has a 12-month low of $1.48 and a 12-month high of $4.56.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.07. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%. The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million.

Institutional Trading of Cardiff Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the business. Laurion Capital Management LP raised its position in Cardiff Oncology by 7.3% during the fourth quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock valued at $7,437,000 after buying an additional 180,866 shares during the period. Acorn Capital Advisors LLC grew its stake in Cardiff Oncology by 39.3% during the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after acquiring an additional 553,317 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after purchasing an additional 104,409 shares during the period. Franklin Resources Inc. purchased a new stake in shares of Cardiff Oncology in the fourth quarter worth approximately $3,388,000. Finally, State Street Corp boosted its holdings in shares of Cardiff Oncology by 4.0% during the fourth quarter. State Street Corp now owns 1,191,647 shares of the company’s stock worth $3,349,000 after purchasing an additional 45,288 shares during the period. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.